Ignite Creation Date:
2024-05-06 @ 8:06 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06258304
Status:
RECRUITING
Last Update Posted:
2024-05-28
First Post:
2024-02-06
Brief Title:
A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Sponsor:
GigaGen Inc
Organization:
GigaGen Inc
Study Overview
Official Title:
A Phase 1 Dose Escalation and Expansion Study of GIGA-564 a Minimally Blocking Anti-CTLA-4 Monoclonal Antibody in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the safety and tolerability of GIGA-564 and identify the maximum tolerated dose MTD and recommended Phase 2 dose RP2D levels of GIGA-564 in participants with metastatic or locally advanced solid tumor malignancies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None